文献速递脑血管病

WAKE-UP试验中卒中患者静脉阿替普酶治疗后的患者报告生活质量

Patient-Reported Quality of Life After Intravenous Alteplase for Stroke in the WAKE-UP Trial.
PubMed 文献 · Neurology · 2022-10-27

WAKE-UP是一项多中心随机安慰剂对照试验,评估MRI引导下静脉阿替普酶对发病时间不明卒中患者90天健康相关生活质量的影响。在490例卒中存活者中,452例有EQ-5D数据,阿替普酶组226例、安慰剂组226例。阿替普酶组EQ-5D指数和EQ VAS均高于安慰剂组, adjusted mean difference分别为0.07(95% CI 0.02-0.12, p=0.005)和7.6(95% CI 3.9-11.8, p<0.001)。

要点

  • 阿替普酶组90天EQ-5D指数均值0.75 vs 安慰剂组0.67,校正均差0.07(95% CI 0.02-0.12, p=0.005)。
  • 阿替普酶组EQ VAS均值72.6 vs 安慰剂组64.9,校正均差7.6(95% CI 3.9-11.8, p<0.001)。
  • EQ-5D指数总治疗效应的85%由mRS评分介导,无显著直接效应;EQ VAS效应主要经直接通路(60%),40%由mRS介导。

核心结论

  • 患者报告结局评估显示,静脉阿替普酶对健康相关生活质量的潜在获益超出功能结局的改善。

研究设计与样本

  • WAKE-UP为多中心、随机、安慰剂对照试验,纳入发病时间不明的卒中患者,接受MRI引导下静脉阿替普酶治疗。
  • 490例卒中存活者中,452例(92.2%)有90天EQ-5D数据,阿替普酶组226例(50%)、安慰剂组226例(50%)。

主要发现

  • 90天EQ-5D指数均值阿替普酶组0.75 vs 安慰剂组0.67,校正均差0.07(95% CI 0.02-0.12, p=0.005)。
  • 90天EQ VAS均值阿替普酶组72.6 vs 安慰剂组64.9,校正均差7.6(95% CI 3.9-11.8, p<0.001)。
  • EQ-5D指数总治疗效应的85%由mRS评分介导,无显著直接效应。
  • EQ VAS治疗效应主要经直接通路(60%),40%由mRS介导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Intravenous alteplase improves functional outcome after acute ischemic stroke. However, little is known about the effects on self-reported health-related quality of life (HRQoL). METHODS: WAKE-UP was a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in stroke with unknown onset time. HRQoL was assessed using the EuroQol five-dimensional questionnaire (EQ-5D) at 90 days, comprising the EQ-5D index and the EQ visual analogue scale (VAS). Functional outcome was assessed by the modified Rankin Scale (mRS). We calculated the effect of treatment on EQ-5D index and EQ VAS using multiple linear regression models. Mediation analysis was performed on stroke survivors to explore the extent to which the effect of alteplase on HRQoL was mediated by functional outcome. RESULTS: Among 490 stroke survivors, the EQ-5D index was available for 452 (92.2%), of whom 226 (50%) were assigned to treatment with alteplase and 226 (50%) to placebo. At 90 days, mean EQ-5D index was higher, reflecting a better health state, in patients randomized to treatment with alteplase than with placebo (0.75 vs 0.67) with an adjusted mean difference of 0.07 (95% CI 0.02-0.12, p = 0.005). In addition, mean EQ VAS was higher with alteplase than with placebo (72.6 vs 64.9), with an adjusted mean difference of 7.6 (95% CI 3.9-11.8, p < 0.001). Eighty-five percent of the total treatment effect of alteplase on the EQ-5D index was mediated using the mRS score while there was no significant direct effect. By contrast, the treatment effect on the EQ VAS was mainly through the direct pathway (60%), whereas 40% was mediated by the mRS. DISCUSSION: Assessment of patient-reported outcome measures reveals a potential benefit of intravenous alteplase for HRQoL beyond improvement of functional outcome. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov number, NCT01525290; EudraCT number, 2011-005906-32.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jensen M, Sehner S, Cheng B, et al. Patient-Reported Quality of Life After Intravenous Alteplase for Stroke in the WAKE-UP Trial. Neurology. 2022. PMID: 36302662. doi:10.1212/WNL.0000000000201375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。